Shattuck Labs (NASDAQ:STTK) Given “Buy” Rating at HC Wainwright

Shattuck Labs (NASDAQ:STTK)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They presently have a $28.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 155.01% from the company’s previous close.

Separately, Needham & Company LLC restated a “buy” rating and set a $12.00 price target on shares of Shattuck Labs in a research note on Tuesday, April 9th.

Shattuck Labs Stock Performance

STTK stock traded up $0.12 during midday trading on Thursday, reaching $10.98. The company’s stock had a trading volume of 145,466 shares, compared to its average volume of 357,132. The stock has a fifty day simple moving average of $9.34 and a two-hundred day simple moving average of $6.85. Shattuck Labs has a 1 year low of $1.33 and a 1 year high of $11.58. The firm has a market capitalization of $522.10 million, a price-to-earnings ratio of -5.34 and a beta of 1.98.

Shattuck Labs (NASDAQ:STTK) last released its earnings results on Thursday, February 29th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.10. Shattuck Labs had a negative return on equity of 63.08% and a negative net margin of 5,268.44%. The business had revenue of $0.71 million for the quarter, compared to analyst estimates of $0.50 million. As a group, analysts forecast that Shattuck Labs will post -1.85 EPS for the current fiscal year.

Insider Activity

In related news, insider Stephen Stout sold 16,004 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $10.53, for a total transaction of $168,522.12. Following the sale, the insider now owns 74,437 shares of the company’s stock, valued at $783,821.61. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 9.89% of the company’s stock.

Institutional Investors Weigh In On Shattuck Labs

A number of institutional investors have recently added to or reduced their stakes in STTK. Tower Research Capital LLC TRC boosted its holdings in Shattuck Labs by 79.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 13,553 shares of the company’s stock worth $97,000 after acquiring an additional 5,989 shares in the last quarter. Cannon Global Investment Management LLC acquired a new stake in Shattuck Labs in the first quarter worth about $91,000. Reliant Investment Management LLC acquired a new stake in Shattuck Labs in the fourth quarter worth about $143,000. SG Americas Securities LLC acquired a new stake in Shattuck Labs in the fourth quarter worth about $268,000. Finally, Pinnacle Associates Ltd. boosted its holdings in Shattuck Labs by 13.9% in the first quarter. Pinnacle Associates Ltd. now owns 521,246 shares of the company’s stock worth $4,660,000 after acquiring an additional 63,800 shares in the last quarter. Institutional investors own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.